The COVID-19 pandemic had a significant impact on the economy in 2020. The introduction of the vaccine before the turn of the year boosted expectations of a return to routine and a faster recovery from the infection. The spread of the Delta strain of the virus in recent days has reignited fears of protracted lockdowns. Investors who have learned from the March 2020 market lockout have already begun hunting for new and exciting opportunities. ViacomCBS, Zynga, MongoDB, and Znaga are just a few of these companies. The technological, biopharmaceutical, and ecommerce industries are expected to be unaffected by the coronavirus ban.
Here is Insider Monkey’s list of the 15 stocks that will double in 2021. Allakos Inc. is a biopharmaceutical company in the clinical stage. Over the last year, the stock has returned 1.4 percent to investors. In the selection of 15 stocks that will double in 2021, Allakos is ranked fifteenth. Funko, Inc. is rated fourteenth. Over the last year, investors have received a 230 percent return on their investment in the company’s stock. Pop culture merchandise is sold by Funko. Paramount Group, Inc. is ranked thirteenth. The company owns and manages a real estate investment trust that specializes in high-end properties in prime business districts. On July 27, the company reported second-quarter results, which were $0.02 higher than market expectations. BHP Group is rated 12th. Over the last year, the stock has provided investors with returns of more than 43%. On July 21, the company established a nickel supply agreement with Tesla, an electric vehicle manufacturer. Genpact Limited is ranked ninth. Over the last few months, the company’s stock has provided investors with returns of more than 22%. The company reported profits for the first quarter on May 10th, with earnings per share of $0.59. Deciphera Pharmaceuticals, Inc. is ranked ninth. The company is based in Waltham, Massachusetts, and produces and sells biopharmaceutical products. Deciphera stated that a patient in an early-stage trial received the first dosage of a novel cancer medication. Affimed N.V. is ranked ninth. In the last year, investors have received a 92 percent return on their investment in the company’s stock. It’s a German biopharmaceutical business that specializes in cancer immunotherapies. For more details, click 15 Stocks That Will Double in 2021.
Pixabay
